Residency · Residency · Infectiousdisease

Sepsis and Septic Shock - Pathophysiology and Management

Definitions (Sepsis-3, 2016)

Current Definitions

The Sepsis-3 consensus definitions, published in 2016, represented a fundamental shift in how sepsis is conceptualized and diagnosed. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Operationally, this is identified as a suspected or documented infection accompanied by an increase in the Sequential Organ Failure Assessment score of two or more points, reflecting clinically significant organ dysfunction. This definition moved away from the older paradigm that equated sepsis with the systemic inflammatory response syndrome triggered by infection.

Septic shock is defined as a subset of sepsis in which particularly profound circulatory and cellular or metabolic dysfunction substantially increases mortality. The operational criteria for septic shock require that the patient has sepsis, requires vasopressor therapy to maintain a mean arterial pressure of at least 65 mmHg, and has a serum lactate level greater than 2 mmol/L despite adequate fluid resuscitation. The combination of vasopressor dependence and hyperlactatemia identifies patients with the highest mortality risk.

The systemic inflammatory response syndrome criteria, which formed the basis of earlier sepsis definitions, are no longer used to define sepsis due to their excessive sensitivity and poor specificity. SIRS criteria are met by many non-infectious conditions, including pancreatitis, burns, and post-surgical states, limiting their diagnostic utility. However, SIRS criteria remain in use in some clinical screening protocols for the early identification of patients who may be developing sepsis.

The quick SOFA score provides a bedside screening tool that does not require laboratory values. A qSOFA score of two or more, based on the presence of altered mental status with a Glasgow Coma Scale below 15, systolic blood pressure of 100 mmHg or less, and respiratory rate of 22 or greater, identifies patients at risk for poor outcomes from infection. Importantly, qSOFA is a prognostic tool for identifying patients who warrant closer evaluation for organ dysfunction, not a diagnostic criterion for sepsis itself.

Epidemiology

Sepsis represents an enormous public health burden. Approximately 1.7 million cases of sepsis are diagnosed annually in the United States, resulting in approximately 270,000 sepsis-related deaths. Sepsis is the leading cause of death in United States hospitals and the most common reason for admission to the intensive care unit. Mortality rates vary substantially by severity, with sepsis carrying a mortality of 10 to 20 percent and septic shock carrying a mortality of 30 to 50 percent. Importantly, survivors of sepsis face significant long-term morbidity through the post-sepsis syndrome, which encompasses cognitive impairment, functional disability, and an increased risk of death in the years following the acute episode.

Pathophysiology

Innate Immune Activation

The pathophysiology of sepsis begins with the recognition of microbial components by the innate immune system. Pathogen-associated molecular patterns, or PAMPs, are conserved microbial structures that include lipopolysaccharide from gram-negative organisms, lipoteichoic acid from gram-positive organisms, peptidoglycan, flagellin, and viral nucleic acids. In addition, damage-associated molecular patterns, or DAMPs, are endogenous molecules released from injured host cells and include high-mobility group box 1 protein, mitochondrial DNA, and histones. These molecules are recognized by pattern recognition receptors expressed on innate immune cells, including Toll-like receptor 4, which recognizes LPS, Toll-like receptor 2, which recognizes gram-positive cell wall components, NOD-like receptors, and inflammasome complexes. Engagement of these receptors triggers activation of the transcription factor NF-kB, initiating the production and release of pro-inflammatory cytokines, including tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8.

The Cytokine Storm and Beyond

The initial pro-inflammatory phase of sepsis is driven by the release of TNF-alpha and IL-1, which produce the cardinal hemodynamic and physiologic disturbances of sepsis: fever, vasodilation, capillary leak, and activation of the coagulation cascade. Complement activation through the generation of anaphylatoxins C3a and C5a amplifies the inflammatory response and drives further neutrophil activation and tissue injury.

Activation of the coagulation cascade represents a critical pathophysiologic event in sepsis. Tissue factor expression on monocytes and endothelial cells triggers the extrinsic coagulation pathway, leading to disseminated intravascular coagulation with simultaneous consumption of natural anticoagulant proteins, including protein C and antithrombin. The resulting widespread microvascular thrombosis contributes directly to organ dysfunction.

Endothelial dysfunction is increasingly recognized as a central mediator of sepsis pathophysiology. The endothelial glycocalyx, a protective carbohydrate-rich layer lining the vascular endothelium, undergoes degradation and shedding during sepsis. Loss of glycocalyx integrity leads to increased vascular permeability, interstitial edema, and the distributive shock physiology that characterizes sepsis.

Immunoparalysis (Late Phase)

While the early phase of sepsis is dominated by pro-inflammatory responses, a concurrent and subsequent compensatory anti-inflammatory response syndrome, or CARS, emerges as a major determinant of late sepsis outcomes. This phase is characterized by the release of anti-inflammatory cytokines, including interleukin-10 and transforming growth factor-beta, and by the apoptosis of immune effector cells.

Sepsis-induced immunosuppression, or immunoparalysis, involves multiple arms of the immune system. Lymphocyte apoptosis depletes both CD4 and CD8 T-cell populations. Monocytes undergo functional deactivation, manifest as reduced expression of HLA-DR, and T cells develop an exhausted phenotype with upregulation of inhibitory receptors. This state of immune dysfunction predisposes survivors of the initial sepsis episode to secondary infections, including healthcare-associated infections and reactivation of latent viruses. Immunoparalysis is now recognized as a major contributor to late sepsis mortality and has emerged as a therapeutic target. Immunostimulatory therapies under investigation include granulocyte-macrophage colony-stimulating factor, interleukin-7, and checkpoint inhibitors such as anti-PD-1 antibodies.

<image>A detailed pathophysiology diagram of sepsis showing the cascade from infection to organ dysfunction. Start with a bacterium releasing PAMPs (LPS) at the top. Show PAMPs binding to TLR4 on a macrophage. The macrophage releases pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6) into the bloodstream. Show three downstream pathways: (1) "Vasodilation" - nitric oxide production → vascular smooth muscle relaxation → distributive shock. (2) "Endothelial dysfunction" - glycocalyx shedding → capillary leak → tissue edema. (3) "Coagulation activation" - tissue factor → thrombin generation → microvascular thrombosis (DIC) + consumption of protein C/antithrombin. Show the final common pathway: "Organ dysfunction" with icons for lungs (ARDS), kidneys (AKI), liver (hepatic dysfunction), brain (encephalopathy), heart (cardiomyopathy). Include a sidebar showing the late phase: "Immunoparalysis" with lymphocyte apoptosis and secondary infection risk. Use a molecular biology/immunology illustration style with clear arrows and labels.</image>

Management - Surviving Sepsis Campaign 2021

Hour-1 Bundle

The Surviving Sepsis Campaign 2021 guidelines establish a structured approach to the initial management of sepsis and septic shock through the Hour-1 Bundle, emphasizing that all key interventions should be initiated within the first hour of sepsis recognition. The bundle consists of five simultaneous actions that should be pursued in parallel rather than sequentially.

Serum lactate should be measured immediately, and if the initial value exceeds 2 mmol/L, it should be remeasured within two to four hours to assess the trajectory. Blood cultures from at least two separate sites should be obtained before antibiotics are administered, though the critical caveat is that antibiotics must never be delayed if cultures cannot be obtained rapidly. Broad-spectrum antibiotics should be administered within one hour of sepsis recognition. For patients with hypotension or a lactate level of 4 mmol/L or greater, rapid intravenous fluid resuscitation with 30 milliliters per kilogram of crystalloid should be initiated, with the goal of completing this initial bolus within three hours. Vasopressors should be applied if the patient remains hypotensive during or after fluid resuscitation, with a target mean arterial pressure of at least 65 mmHg.

Antibiotic Therapy

The timing of antibiotic administration is the single most impactful modifiable variable in sepsis management after source control. The landmark study by Kumar and colleagues in 2006 demonstrated that each hour of delay in the initiation of effective antibiotic therapy increases mortality by approximately 4 to 8 percent. This finding underscores the imperative for immediate empiric antibiotic administration.

Empiric antibiotic selection should be broad-spectrum and guided by the suspected source of infection, the local antibiogram, and patient-specific risk factors for resistant organisms. Once culture and susceptibility data are available, typically within 48 to 72 hours, the antibiotic regimen should be de-escalated to the narrowest effective spectrum. The duration of antibiotic therapy should be the shortest effective course, with 7 to 8 days being appropriate for most infections. Notable exceptions requiring longer courses include endocarditis, osteomyelitis, and Staphylococcus aureus bacteremia.

Procalcitonin-guided antibiotic discontinuation offers a strategy for further reducing unnecessary antibiotic exposure. Serial procalcitonin measurements can guide discontinuation when levels fall below 0.5 nanograms per milliliter or decline by more than 80 percent from the peak value. Trials including PRORATA and SAPS have demonstrated that this approach reduces antibiotic exposure by two to three days without adverse outcomes.

Fluid Resuscitation

Initial fluid resuscitation with 30 milliliters per kilogram of intravenous crystalloid remains the standard recommendation of the Surviving Sepsis Campaign 2021, though the fixed-volume approach has been challenged by more recent data. The CLOVERS and CLASSIC trials suggest that a more conservative, restrictive fluid strategy may be non-inferior to the liberal approach, and clinical practice is evolving toward individualized fluid administration guided by dynamic assessment of fluid responsiveness.

Among crystalloid solutions, balanced crystalloids such as Lactated Ringer's solution and Plasmalyte are preferred over 0.9 percent normal saline. The SMART trial demonstrated a reduction in the composite outcome of major adverse kidney events at 30 days with balanced crystalloids compared with normal saline. Albumin may be considered when large volumes of crystalloid are required, though the SAFE trial demonstrated no clear mortality benefit; albumin may reduce the total fluid volume administered.

Hydroxyethyl starch solutions are absolutely contraindicated in sepsis. The 6S and CHEST trials conclusively demonstrated that HES increases both mortality and the incidence of acute kidney injury requiring renal replacement therapy, leading to regulatory warnings and withdrawal from use in critically ill patients.

Dynamic assessment of fluid responsiveness should guide ongoing resuscitation decisions. Techniques including passive leg raise testing, pulse pressure variation, inferior vena cava variability assessed by ultrasound, and stroke volume variation provide real-time information about whether additional fluid administration is likely to increase cardiac output. Static central venous pressure targets have been shown to be poor predictors of fluid responsiveness and are no longer recommended as resuscitation endpoints.

Vasopressors

Norepinephrine is the first-line vasopressor for septic shock, providing predominantly alpha-1 adrenergic vasoconstriction with a modest beta-1 inotropic effect. The target mean arterial pressure is at least 65 mmHg, and norepinephrine should be initiated promptly when hypotension persists despite initial fluid resuscitation, or even concurrent with fluid administration in patients with severe hypotension.

Vasopressin at 0.03 to 0.04 units per minute is the recommended second-line agent, added to norepinephrine when the norepinephrine dose exceeds 0.25 to 0.5 micrograms per kilogram per minute. The VASST trial demonstrated a catecholamine-sparing effect, allowing reduction in norepinephrine dose. Vasopressin acts through a mechanism independent of catecholamine receptors, providing synergistic vasoconstriction.

Epinephrine is the third-line vasopressor, added when norepinephrine and vasopressin are insufficient to achieve hemodynamic targets. Epinephrine provides potent beta-1 stimulation and may be particularly useful when cardiac dysfunction accompanies septic shock. Clinicians should be aware that epinephrine can elevate lactate levels through beta-2 mediated glycogenolysis, an effect that does not necessarily indicate worsening tissue perfusion and should not be reflexively interpreted as such.

Phenylephrine, a pure alpha-1 agonist, is rarely used and may be appropriate in the specific clinical scenario of tachyarrhythmia-limited patients in whom additional beta-1 stimulation would be deleterious. Angiotensin II, marketed as Giapreza, acts through a vasopressin type 1 receptor-independent pathway and was evaluated in the ATHOS-3 trial, which demonstrated a MAP response in patients with catecholamine-refractory shock. It represents an option for truly refractory vasodilatory shock, though its high cost limits widespread adoption.

Dopamine should be avoided in septic shock. The study by De Backer and colleagues in 2010 demonstrated a higher rate of arrhythmias and a trend toward increased mortality with dopamine compared to norepinephrine.

Corticosteroids in Septic Shock

Corticosteroids are indicated for septic shock that is refractory to fluids and vasopressors, typically when the norepinephrine dose reaches or exceeds 0.25 micrograms per kilogram per minute and has been required for at least four hours. The recommended regimen is hydrocortisone 200 milligrams per day, administered either as 50 milligrams intravenously every six hours or as a continuous infusion, for approximately seven days followed by a taper.

Two major trials published in 2018 provided the evidentiary foundation for current practice. The ADRENAL trial evaluated hydrocortisone alone in septic shock and found no 90-day mortality benefit but demonstrated faster shock reversal, shorter ICU stay, and fewer blood transfusions. The APROCCHSS trial evaluated the combination of hydrocortisone and fludrocortisone in septic shock and demonstrated a significant 90-day mortality benefit, with mortality of 43 percent in the treatment group versus 49.1 percent in the placebo group. Current practice among most intensivists is to use hydrocortisone with or without fludrocortisone for vasopressor-dependent septic shock, with initiation early in the course when vasopressor requirements are escalating.

<image>A step-by-step management protocol for sepsis and septic shock based on the Surviving Sepsis Campaign 2021 Hour-1 Bundle. Create a vertical timeline starting at "Time 0: Sepsis Recognized." Show five parallel action items in the first hour: "1. Measure serum lactate (repeat if >2)," "2. Blood cultures x2 (before antibiotics)," "3. Broad-spectrum antibiotics (within 1 hour)," "4. IV crystalloid 30 mL/kg if hypotension or lactate ≥4," "5. Vasopressors if MAP <65 after fluid bolus (norepinephrine first-line)." At the 3-hour mark: "Reassess volume status (dynamic measures: PLR, PPV, IVC variability), repeat lactate." At 6 hours: "Re-evaluate -- if still on vasopressors: add vasopressin 0.04 U/min as second agent; consider hydrocortisone 200mg/day if refractory shock." Include decision points for "Fluid responsive?" (yes → more fluid, no → stop fluids, start/uptitrate vasopressors). Use the SSC traffic light format with red for critical actions.</image>

Organ-Specific Management

ARDS in Sepsis

Acute respiratory distress syndrome is one of the most common and consequential organ dysfunctions in sepsis. Lung-protective ventilation using a tidal volume of 6 milliliters per kilogram of ideal body weight is the cornerstone of management, as established by the ARDSNet trial. Plateau pressure should be maintained below 30 centimeters of water to minimize ventilator-induced lung injury. PEEP titration should follow established protocols, with higher PEEP levels applied for moderate to severe ARDS using FiO2/PEEP tables.

Prone positioning is indicated for patients with a PaO2-to-FiO2 ratio below 150 and should be maintained for a minimum of 16 hours per day. The PROSEVA trial demonstrated a significant mortality benefit with prone positioning in moderate to severe ARDS. Once the patient is hemodynamically stabilized, a conservative fluid strategy should be adopted, as demonstrated by the FACTT trial, targeting an even or negative fluid balance to reduce pulmonary edema and improve oxygenation.

Acute Kidney Injury

Management of acute kidney injury in sepsis centers on avoiding nephrotoxic agents and optimizing renal perfusion pressure. The timing of renal replacement therapy initiation has been clarified by the STARRT-AKI and IDEAL-ICU trials, both of which demonstrated no benefit to early initiation of RRT. Standard indications for RRT should be applied, including refractory metabolic acidosis, life-threatening hyperkalemia, refractory volume overload, and uremic symptoms.

Sepsis-Induced Coagulopathy/DIC

The management of disseminated intravascular coagulation in sepsis is primarily directed at treating the underlying infection through source control and appropriate antibiotic therapy. Blood product transfusion is guided by clinical bleeding: platelets should be transfused for counts below 50,000 in the setting of active bleeding, fresh frozen plasma is indicated for prolonged coagulation parameters with bleeding, and cryoprecipitate should be administered for fibrinogen levels below 100 to 150 milligrams per deciliter. Systemic anticoagulation for DIC is not routinely recommended unless the clinical phenotype is predominantly thrombotic rather than hemorrhagic.

Source Control

Principles

Source control is a foundational principle in the management of sepsis that is equal in importance to antibiotic therapy. The goal is to identify and eliminate the focus of infection through drainage of abscesses, debridement of necrotic or infected tissue, removal of infected devices, or surgical repair of perforated viscera. Source control should be achieved within 6 to 12 hours of diagnosis whenever feasible.

The critical concept is that antibiotics alone are insufficient to resolve sepsis when an undrained collection or uncontrolled source is present. An undrained abscess, a perforated viscus, or an infected prosthetic device will perpetuate the septic response regardless of the potency or appropriateness of the antibiotic regimen. Cross-sectional imaging with CT and intravenous contrast is essential for identifying drainable collections, and interventional radiology should be engaged early for percutaneous drainage when surgical intervention is not immediately required or feasible.

Lactate as a Biomarker

Interpretation

Elevated lactate in sepsis reflects a combination of tissue hypoperfusion, classified as type A hyperlactatemia, and stress-related aerobic glycolysis driven by catecholamine excess. The recognition that sepsis-associated hyperlactatemia is not solely a marker of anaerobic metabolism has refined the clinical interpretation of this biomarker, though it remains one of the most important prognostic indicators available.

Lactate clearance, defined as the percentage decline in lactate over time, is a more clinically useful measure than any single static value. A target of at least 20 percent reduction in lactate over two to six hours is a reasonable resuscitation goal, and failure to clear lactate predicts poor outcomes. Serial lactate monitoring should guide resuscitation decisions and has been shown to reduce mortality when incorporated into protocolized care. The ANDROMEDA-SHOCK trial demonstrated that capillary refill time could serve as an alternative resuscitation target and was non-inferior to lactate-guided resuscitation, offering a simple bedside assessment that complements biochemical monitoring.

Key Clinical Pearls

• Antibiotics within 1 hour of sepsis recognition is the most impactful intervention after source control -- every hour of delay increases mortality
• Norepinephrine is the first-line vasopressor for septic shock -- dopamine is associated with more arrhythmias and should be avoided
• Use balanced crystalloids (LR, Plasmalyte) over normal saline -- SMART trial showed reduced major adverse kidney events
• Hydroxyethyl starch is CONTRAINDICATED in sepsis -- increases mortality and renal failure
• Dynamic measures of fluid responsiveness (passive leg raise, pulse pressure variation) are preferred over static CVP targets
• Corticosteroids in septic shock (hydrocortisone 200mg/day) hasten shock reversal even if mortality benefit remains debated
• Source control is as important as antibiotics -- an undrained abscess or unremoved infected device will prevent sepsis resolution regardless of antibiotic choice
• Post-sepsis immunosuppression (immunoparalysis) is increasingly recognized as a major contributor to late sepsis mortality and secondary infections

References

1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810.
2. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063-e1143.
3. Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock (APROCCHSS). N Engl J Med. 2018;378(9):809-818.
4. Semler MW, Self WH, Wanderer JP, et al. Balanced crystalloids versus saline in critically ill adults (SMART). N Engl J Med. 2018;378(9):829-839.
5. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-1596.

Read this lecture as Markdown